Omega Therapeutics (NASDAQ:OMGA) reported quarterly losses of $(0.30) per share which missed the analyst consensus estimate of $(0.28) by 7.14 percent. The company reported quarterly sales of $2.612 million which beat the analyst consensus estimate of $1.240 million by 110.56 percent. This is a 214.32 percent increase over sales of $831.000 thousand the same period last year.
Clear
All
Quotes
News
Learn
Help
All
HK
US
CN
SG
AU
JP
All
News
Announcements
Reports
No matches yet
Operations too frequent. Please try again later.
Please check network settings and try again Refresh
Refresh
Loading
History record
Latest News
-
Trump will return to the White House next week! What are the important processes for the inauguration ceremony? Please keep this observation and Trade guide.
AI demand has once again been proven! Taiwan Semiconductor's Q4 net profit increased by 57% year-on-year, exceeding expectations, with gross margin rising to 59%.
Taiwan Semiconductor's stock price is nearing a historical high! The "King of Asia's Stocks" exceeded expectations in Q4 performance, driving the Semiconductors Sector to collectively strengthen.
Quotes
More
News
More
Learn
More
Help
More
Loading
News
More
Announcements
More
Reports
More
Omega Therapeutics Q3 2024 GAAP EPS $(0.30) Misses $(0.28) Estimate, Sales $2.612M Beat $1.240M Estimate
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Like
Comment(0)
Reason For Report